Herborium Group to Begin Commercialization of its All Natural Sexual Health Products With Aggressive Plans to Take a Bite of a 3.2 Billion Dollar Market
Herborium to sell products for both Men and Women based on Traditional Chinese Medicine with a 98% efficacy rate with no side effects
Press Release: Herborium Group, Inc. — Thu, Mar 1, 2012 7:00 AM ESTTEANECK, N.J., March 1, 2012 /PRNewswire/ -- Herborium Group, Inc., (Pink Sheets: HBRM) www.herborium.com, aBotanical Therapeutics® company, announce today a plan to commercialize its sexual health proprietary Botanical Therapeutics® in 2012. The market for pharmaceutical gradesexual health products is over 3.2 billion worldwide with Viagra (Pfizer), Cialis (Eli Lilly) and Levitra (Bayer) leading market share. The market for natural sexual health products is estimated to be over $1.5 billion and growing. The rising costs of pharmaceutical grade sexual health drugs together with some safety concerns drive consumers to look for alternatives in the market for natural sexual health products.
In addition there is a growing need for women sexual health products. In fact the female sexual enhancement industry is expected to grow into a multibillion dollar business. Long considered a taboo subject, women's sexuality is now openly discussed and portrayed on television, in magazines, and on the internet. Most importantly, women themselves are becoming increasingly aware of their sexuality and their sexual health. First-quarter sales of personal lubricants soared 32% to $41.2 million, according to Information Resources Inc. There is no Viagra comparative product on the market for women.
Dr. Agnes Olszewski, Chairman and CEO of Herborium, stated: "We believe that this is the right time to commercialize our all herbal, proprietary products for men and women. There is nothing on the market as our systemic all herbal product for women. Unlike many supplements claiming to improve sexual performance and libido both our products include only herbal ingredients recognized for their safety. Both products developed by Herborium are based on a combination of Principles of Traditional Chinese Medicine and modern sexual health science, have confirmed up to 98% efficacy and improve performance and experience for those men and women with sexual performance problems and those seeking recreational sexual enhancement. Products have no know adverse effects."
"By combining unique characteristics of Herborium sexual health Botanical Therapeutics® with our social media marketing strategy and growing demand and awareness regarding sexual health, we expect our products to gain market acceptance and revenue generating status in 2012," concluded Dr. Olszewski.
About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. The company sales its products in the US and Europe. For more information, please visit www.herborium.com and www.acnease.com.
One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.
For more information please inquire: Investorsrelations@herborium.com
"As we have stated in our Press Release of 02/24/2012 regarding a signed Letter of Intent with China Health Resource Inc., both parties have commenced a due diligence process by now. This process will continue for a duration needed for its completion by both parties. When this process is completed and the actual transaction takes place, the transaction will be promptly announced. While both parties are truly excited about the opportunity they are also committed to meet their fiduciary responsibilities so the due diligence process is and will be conducted in a most responsible and professional manner. We are most optimistic of a smooth transaction and final agreement," concluded Dr. Olszewski.
About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. The company sales its products in the US and Europe. For more information, please visit www.herborium.com and www.acnease.com.
One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.
For more information please inquire: Investorsrelations@herborium.com
News & Events view all »
Investors News Sign Up
Contact Herborium Group, Inc.
E-mail: InvestorsRelations@Herborium.com